Apolipoprotein E in diet-induced obesity: a paradigm shift from conventional perception

Kyriakos E. Kypreos✉, Eleni A. Karavia, Caterina Constantinou, Aikaterini Hatziri, Christina Kalogeropoulou, Eva Xepapadaki, Evangelia Zvintzou

Department of Pharmacology, University of Patras Medical School, Rio Achaias, TK 26500, Greece.

Abstract

Apolipoprotein E (APOE) is a major protein component of peripheral and brain lipoprotein transport systems. APOE in peripheral circulation does not cross the blood brain barrier or blood cerebrospinal fluid barrier. As a result, peripheral APOE expression does not affect brain APOE levels and vice versa. Numerous epidemiological studies suggest a key role of peripherally expressed APOE in the development and progression of coronary heart disease while brain APOE has been associated with dementia and Alzheimer’s disease. More recent studies, mainly in experimental mice, suggested a link between Apoe and morbid obesity. According to the latest findings, expression of human apolipoprotein E3 (APOE3) isoform in the brain of mice is associated with a potent inhibition of visceral white adipose tissue (WAT) mitochondrial oxidative phosphorylation leading to significantly reduced substrate oxidation, increased fat accumulation and obesity. In contrast, hepatically expressed APOE3 is associated with a notable shift of substrate oxidation towards non-shivering thermogenesis in visceral WAT mitochondria, leading to resistance to obesity. These novel findings constitute a major paradigm shift from the widely accepted perception that APOE promotes obesity via receptor-mediated postprandial lipid delivery to WAT. Here, we provide a critical review of the latest facts on the role of APOE in morbid obesity.

Keywords: apolipoprotein E, morbid obesity, white adipose tissue, energy metabolism

Adipose organ overview

Adipose organ is made of white adipose tissue (WAT) that is mainly responsible for lipid storage, and brown adipose tissue (BAT) that is mainly responsible for energy production (heat and ATP). Under certain circumstances, WAT may be activated metabolically and turn into BRITE (BRown Into whiTE) adipose tissue that is able to produce heat via non-shivering thermogenesis, but localizes in WAT depots[1]. Increased non-shivering thermogenesis is a result of elevated mitochondrial metabolic activity and mainly uncoupling protein 1 (Ucp1) function that mediates the metabolic conversion of free fatty acids to heat, thus contributing to the lean phenotype[2–3]. However, induction of WAT mitochondrial oxidative phosphorylation for ATP production, independently of Ucp1 increase, may also contribute to the lean phenotype[4]. The origin of newly formed brown adipocytes in adipose organ following exposure of animals to cold

✉Corresponding author: Kyriakos E. Kypreos, Ph.D., Department of Pharmacology, University of Patras Medical School, Panepistimiopolis, Rio Achaias, TK 26500, Greece. Tel/Fax: +302610969120/+302610994720, E-mail: kkypreos@med.upatras.gr, Web: https://www.kyriakoskypreos.com.

Received 19 January 2018, Revised 06 March 2018, Accepted 8 March 2018, Epub 09 April 2018
expression in these two species\[15\]. Apoe suggesting that differences also exist in the regulation of more upstream of the two species transcription start site, significantly with less than 40% homology at 180 bp or more upstream of the two species transcription start site, suggesting that differences also exist in the regulation of Apoe expression in these two species\[15\].

It is well-established that the brain is isolated from peripheral blood circulation and consequently from peripheral organs\[16\] by i) the blood brain barrier (BBB) formed by cerebrovascular endothelial cells\[17\], and ii) by the blood-cerebrospinal fluid barrier (BCSFB) composed of cuboidal epithelial cells of the choroid plexus\[18\]. Free cholesterol cannot cross either BBB or BCSFB\[19\], thus all brain cholesterol originates from local de novo biosynthesis. However, it has been shown that some oxysterols that result from peripheral cholesterol oxidation can diffuse through BBB to both directions and possibly fulfill yet unexplored roles in cholesterol signaling and homeostasis\[20\]. Brain cholesterol synthesis is regulated by mechanisms like those observed in peripheral organs and tissues, with hydroxyl-methyl-glutaryl CoA reductase (HMGCoAR) activity defining the rate limiting step. Similarly, APOE in peripheral circulation does not cross either BBB or BCSFB\[21\]. Therefore, brain APOE is locally expressed by astrocytes and microglia\[22\] in its different isoforms ApoE2, ApoE3, and ApoE4 with a frequency of 7%, 78%, and 15%, respectively\[23\].

Interestingly, brain lipoproteins are also different from the lipoproteins present in the peripheral circulation\[16\]. Lipoproteins of human central nervous system (CNS) have been mainly studied in cerebrospinal fluid (CSF) that is readily accessible by noninvasive methods. It is particularly important to note that the APOE and APOB-containing lipoproteins of peripheral circulation, such as low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), chylomicron and chylomicron remnants do not cross BBB or BCSFB and are undetectable in CSF\[21\]. In contrast, CSF lipoproteins have similar size and density to plasma HDL, thus are justifiably defined as "HDL-like particles"\[24\]. Four distinct lipoprotein subpopulations have been identified\[16\]. Notably, APOE and apolipoprotein A1 (APOA1) are the major protein constituents of CSF HDL-like particles\[24\]. Brain APOE has been strongly implicated in mechanisms associated with neurodegenerative diseases including Alzheimer’s disease\[25\].

Peripherally expressed APOE is involved in plasma metabolism and clearance of triglyceride-rich lipoproteins (TRLs) from circulation\[26–27\]. Early work by Havel and coworkers established an inverse correlation between plasma APOE and TRLs levels\[28\], while subsequent work showed that excess plasma APOE is an inhibitor of lipoprotein lipase (LPL). Plasma LPL is activated by Apolipoprotein C2 (APOC2) and inhibited Apolipoprotein C3 (APOC3)\[29\]. Excess APOE may inhibit LPL by displacing APOC2 from TRL particles\[30–31\] or through direct protein-protein interaction where arginine residues in APOE are believed to play important role\[32\].

APOE is also a structural component of HDL. It can promote the formation of HDL-like particles with the participation of lipid transporter ATP binding cassette
A1 (ABCA1) and plasma enzyme Lechithin-cholesterol acyltransferase (LCAT) in a fashion similar to APOA1[33–34]. Numerous epidemiological studies suggested that APOE is associated with the development and progression of coronary heart disease in humans[35–38], an observation that was further confirmed in experimental animals with the creation of the Apoe-deficient (apoe−/−) mouse[39].

**Apolipoprotein E (APOE) in morbid obesity, a paradigm shift**

More recent studies in mice strongly suggest a link between Apoe and morbid obesity. Work by Chiba et al., showed that leptin and Apoe double deficient mice (ob/ob x apoe−/) are resistant to body weight and adipose tissue gain when fed a high-fat/high-cholesterol diet, despite an increase in their plasma VLDL levels[40]. In another study, Huang et al. reported that apoe−/− mice accumulate less body fat content and possess smaller adipocytes compared to wild type C57BL/6 controls[41]. Hofmann and coworkers extended further this observation by showing that apoe−/− mice fed high-fat-high-sucrose diabetogenic diet for 24 weeks were resistant to diet-induced obesity and exhibited improved glucose uptake by muscle and brown adipose tissue[42]. The role of Apoe in obesity was also confirmed in the Ay+ mice where deficiency in Apoe prevented the development of obesity, with decreased fat accumulation in the liver and adipose tissues[43]. Along the same line, mice expressing human APOE3 in place of mouse Apoe (apoe3knock-in) fed the standard western-type diet (21% fat) for 24 weeks were more sensitive to diet-induced obesity and related metabolic dysfunctions than wild-type C57BL/6 mice, while apoe−/− mice were resistant to these conditions[44].

Work in humans confirmed the presence of elevated APOE levels in the plasma of morbidly obese subjects immediately prior to bariatric surgery while six months following the operation, APOE was barely detectable, establishing a correlation between plasma APOE levels and body mass index (BMI)[45].

The important role of APOE in the clearance of TRLs from peripheral circulation led to a widely accepted perception among broader scientific community that APOE promotes obesity via receptor mediated post-prandial lipid delivery to peripheral tissues, including BAT and WAT[46]. Indeed, lipoprotein-bound APOE is a natural ligand for the LDL-receptor (LDLR) and LDLR-related protein 1 (LRP1)[47–49]. APOE3 and APOE4 bind LDLR with a much higher affinity than APOE2[50], while all three isoforms have similar binding affinities for LRP1[51]. However, LDLR has only a minor, if any, contribution to diet-induced obesity. Schreyer and coworkers reported that in contrast to apoe−/− mice that remained lean, Ldlr-deficient (ldlr−/−) mice fed a diabetogenic high-fat high-sucrose diet (35.5% fat mainly from lard and 36.6% carbohydrate mainly from sucrose) became more obese than wild-type mice and developed severe hypertriglyceridemia and hyper-leptinemia[52]. Along the same line, we also found that ldlr−/− mice fed the standard Western-type diet became more obese than apoe−/− mice and developed significant hepatic steatosis[53].

Similarly, despite reports suggesting that adipose tissue Lrp1 may be implicated in diet-induced obesity[54], more recent work showed that in the aP2-cre mouse, significant Cre activity is also found in ganglia of the peripheral nervous system (PNS), in adrenal medulla and in neurons throughout the CNS, proving that the aP2-cre mouse should no longer be used as a tool for adipose-tissue specific inactivation of genes[55–56]. Combining this information, along with our recent data showing that APOE promotes diet-induced obesity independent of its ability to mediate direct peripheral post-prandial lipid delivery to WAT[57], an alternative interpretation of the data of Hofmann et al.[54] is that the obesity resistant phenotype of floxed-lrp1 mice crossed with aP2-cre mice is due to Lrp1 inactivation in PNS and CNS and not in adipose tissue, as originally suggested[54]. Confirming this alternative interpretation, tissue specific deletion of neuronal lrp1 gene in brain resulted in an obese phenotype characterized by increased food intake, decreased energy consumption, and decreased leptin signaling[58]. This finding may further suggest that brain Lrp1 does not mediate the positive effects of brain Apoe on obesity development.

In an effort to investigate the mechanisms of APOE promoted diet-induced obesity, in a recent study, we employed four different mouse models: Apoe−/−, Apoe3brain, Apoe3knock-in, and apoe−/− infected with an adenoassociated virus expressing APOE3 (AAV-E3)[57]. In the Apoe3brain mouse, APOE3 expression is localized specifically in astrocytes and neurupil throughout development and into the adult period, with only trace amounts present in periphery[14]. On the other hand, Apoe3knock-in mice express ubiquitously human APOE3 in place of mouse Apoe[49], while Apoe−/− mice infected with AAV-E3 express APOE3 in the liver which is the natural tropism of the virus[60]. We selected to study APOE3, which is the most common human APOE isoform[8,27,61–65].

Interestingly, peripheral post-prandial lipid deposition to WAT did not correlate with body weight gain and obesity. Moreover, APOE3 exhibited a bimodal relation with visceral WAT mitochondrial metabolic activation.
that was highly dependent on its site of expression (brain vs. periphery) (Fig. 1). Our data showed that brain APOE3 expression in Apoe3brain mice led to a potent inhibition of visceral WAT mitochondrial oxidative phosphorylation and consequently significantly reduced substrate oxidation, increased fat accumulation and obesity. To the contrary, hepatically expressed APOE3 in apoe−/− mice infected with AAV-E3 was associated with a notable shift of substrate oxidation towards non-shivering thermogenesis in visceral WAT mitochondria, associated with resistance to obesity. Of note, brain APOE3-mediated inhibition was dominant over peripheral APOE3-mediated stimulation of WAT mitochondrial metabolic activity. The site-specific effects of APOE3 on obesity were independent of food consumption since all mouse strains consumed similar amounts of calories per day.

In agreement with our results, a very elegant study employing conditional apoe deletion mouse models showed that deletion of WAT-expressed apoe had no effect on morbid obesity while deletion of hepatically-expressed apoe resulted in rather higher adiposity in mice[66], confirming the protective role of hepatically expressed APOE3 in obesity that we identified in our recently published work[57]. Therefore, the increased peripheral APOE levels observed in bariatric subjects prior to surgery[45] may not represent a cause of morbid obesity but rather a protective mechanism triggered in response to nutrient surplus, aiming at promoting excess substrate oxidation in WAT mitochondria for energy production via non-shivering thermogenesis.

**Future directions**

These latest findings constitute a major “paradigm shift” from the existing perception that peripherally expressed APOE promotes obesity via receptor-mediated postprandial lipid delivery to WAT. Contrasting this outdated view, the current data show that increasing hepatically expressed APOE may exert a significant beneficial effect against WAT expansion and morbid obesity development (Fig. 1).

A major undesirable effect associated with increased peripheral wild-type (wt) APOE expression is the induction of severe hypertriglyceridemia and subsequently combined hyperlipidemia (Fig. 2). Indeed, as detailed above plasma APOE levels show a direct correlation with plasma triglyceride levels[28]. Even the subtlest increase of plasma APOE concentration from

![Fig. 1 Effects of brain and peripheral APOE3 expression on visceral WAT mitochondrial metabolic activation.](image-url)

APOE3 expression affects visceral WAT mitochondrial metabolic activation in a fashion that is highly dependent on its site of expression and independent of postprandial dietary lipid deposition. A: Apoe-deficiency is associated with increased WAT mitochondrial oxidative phosphorylation towards ATP production leading to a lean phenotype; B: brain APOE3 expression is associated with a potent inhibition of visceral WAT mitochondrial oxidative phosphorylation leading to significantly reduced substrate oxidation, increased fat accumulation and obesity; C: peripherally expressed APOE3 is associated with a notable shift of substrate oxidation towards non-shivering thermogenesis in visceral WAT mitochondria, leading to resistance to obesity and a lean phenotype; D: Ubiquitously expressed APOE3 (ie. both in brain and periphery) is associated with potent inhibition of visceral WAT mitochondrial oxidative phosphorylation and non-shivering thermogenesis, further suggesting that brain APOE3 has a dominant effect over peripherally expressed APOE3 on WAT mitochondrial metabolism. Green color in mice denotes the site of APOE3 expression.
physiological (2–5 mg/dL), triggers severe hypertriglyceridemia that is due to direct inhibition of plasma LPL activity\(^{32}\) and increased hepatic VLDL production\(^{67}\) (Fig. 2).

A solution to this limitation may be the use of recombinant APOE forms with improved biological functions\(^{47,68–69}\). We showed previously that APOE-induced hypertriglyceridemia requires the carboxyterminal domain 260-299 of APOE\(^{47}\), and specifically helix 8 that extends from aminoacids 260-270\(^{68}\). Using site directed mutagenesis. We created a recombinant APOE form termed APOE4mut1 (apoE4 [L261A, W264A, F265A, L268A, V269A]) that in mice corrects hypercholesterolemia without triggering hypertriglyceridemia even at concentration as high as 170 mg/dL\(^{68}\) (Fig. 2). Additional studies should determine if truncated or mutated APOE forms could also serve as biological anti-obesity drugs for WAT mitochondrial metabolic activation towards non-shivering thermogenesis\(^{47,68}\).

Despite these major advances in the understanding of the role of APOE in morbid obesity, the precise mechanisms underlying its opposing site-specific effects, including the effector molecules mediating the cross-talk between brain APOE and WAT mitochondrial metabolic activity, remain unclear. Importantly, the role of brain APOE-containing lipoproteins in body-weight gain needs further investigation.

**Acknowledgments**

Dr. Eleni A. Karavia and Ms. Eva Xepapadaki are supported by a Postdoc-Research Scholarship (2017-2019), and a graduate studentship (2017-2019) respectively, both funded by the State Scholarships Foundation (I.K.Y) of Greece.

**References**

[1] Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-review[J]. Gerontology, 2012, 58(1): 15–23.
[2] Heeren J, Münzberg H. Novel aspects of brown adipose tissue biology[J]. Endocrinol Metab Clin North Am, 2013, 42(1): 89–107.
[3] Schulz TJ, Tseng YH. Brown adipose tissue: development, metabolism and beyond[J]. Biochem J, 2013, 453(2): 167–178.
[4] Flachs P, Rossmeisl M, Kuda O, et al. Stimulation of mitochondrial oxidative capacity in white fat independent of UCP1: a key to lean phenotype[J]. Biochim Biophys Acta, 2013, 1831(5): 986–1003.
[5] Timmons JA, Wenmalm K, Larsson O, et al. Myogenic gene expression signature establishes that brown and white adipop-
Apolipoprotein E gene is regulated by multiple positive and negative elements [J]. Biochemistry, 1981, 20(4): 1033–1041.

Maiti TK, Konar S, Bir S, et al. Role of apolipoprotein E polymorphism as a prognostic marker in traumatic brain injury and neurodegenerative disease: a critical review [J]. Neurosurg Focus, 2015, 39(5): E3.

Zannis VI, Kypreos KE, Chroni A, et al. Probing the pathways of chylomicron and HDL metabolism using adenosviruses-mediated gene transfer [J]. Curr Opin Lipidol, 2004, 15(2): 151–166.

Seale P, Bjork B, Yang W, et al. PRDM16 controls a brown fat/skeletal muscle switch [J]. Nature, 2008, 454(7207): 961–967.

Buschmann SF, Kappes PM, Zhao Y, et al. Oxysterols modulate cholesterol efflux from mouse aortic and hepatic cells [J]. J Biol Chem, 2012, 287(32): 26749–26759.

McNally BP, Gao Y, Bongiorno AM, et al. The effects of age on cholesterol and lipid metabolism [J]. J Nutr Biochem, 2013, 24(8): 1170–1175.

Farese RV Jr, Frontera AW, et al. Cholesterol and the brown adipose fat cell [J]. Physiol Rev, 2007, 87(2): 249–329.

Apolipoproteins: emerging roles in development, physiology, and disease, and therapy [J]. J Neurosci, 2010, 30(46): 15153–15166.

Huang Y, Liu XQ, Rall SC Jr, et al. Overexpression and transporters and metabolic modulators in the brain [J]. J Intern Med, 2006, 260(6): 493–508.
tissue-specific apolipoprotein E function for hypercholesterolemia and diet-induced obesity\cite{ref1}. *PLoS One*, 2015, 10(12): e0145102.

\[67\] Kypreos KE, van Dijk KW, van Der Zee A, et al. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis *in vivo*. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion\cite{ref2}. *J Biol Chem*, 2001, 276(23): 19778–19786.

\[68\] Kypreos KE, van Dijk KW, Havekes LM, et al. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia\cite{ref3}. *J Biol Chem*, 2005, 280(8): 6276–6284.

\[69\] Drosatos K, Kypreos KE, Zannis VI. Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein\cite{ref4}. *Biochemistry*, 2007, 46(33): 9645–9653.

---

**CLINICAL TRIAL REGISTRATION**

The *Journal* requires investigators to register their clinical trials in a public trials registry for publication of reports of clinical trials in the *Journal*. Information on requirements and acceptable registries is available at [https://clinicaltrials.gov/](https://clinicaltrials.gov/).